Sponsored Symposium
Addressing the MRSA Crisis-A Paradigm Shift Beyond Vancomycin in the ICU
Supported by an educational grant from Astellas Pharma
Release date: March 2010
Expiration date: March 2011
Estimated running time: 1.5 hours

Agenda
The MRSA Crisis: Epidemiological Trends in the ICU
Thomas M. File, Jr., MD, MSc, MACP

Appropriate Use of Vancomycin for MRSA Infections
Michael J. Rybak, PharmD, MPH

Strategies for Selection of Anti-MRSA Agents in the Severely Ill
Donald E. Craven, MD

Learning Objectives
At the conclusion of this activity, participants should be able to:
1. Identify the characteristics and pathogenesis of MRSA infections in the ICU
2. Evaluate how to optimize vancomycin therapy for MRSA infections
3. Select an appropriate antimicrobial agent to treat MRSA infections based on evidence based strategies

SPEAKER DISCLOSURES
Faculty have reported the following disclosures. A copy of SCCM’s policy on resolving conflicts of interest can be found online

Thomas M. File, Jr., MD, MSc, MACP
Northeastern Ohio Universities
Akron, OH, USA
Research funding-- Cerexa, Ortho-McNeil, Protez, Pfizer; Boehringer Ingelheim, Gilead, Tibotec
Consultant/Honoraria—Cerexa/Forest, Glaxo SmithKline, Ortho-McNeil, Protez, Merck, Nabriva, Pfizer, Schering Plough, Wyeth

Michael Rybak, PharmD, MPH
Wayne State University
Detroit, MI, USA
Research grants - Astellas, Cubist, Forest and Pfizer
Consultant - Astellas, Cubist, Forest, Ortho-McNeil, and Targanta
Speaker’s bureaus - Cubist, Novartis, Wyeth, Pfizer, and Targanta. B.M.L.
Consultant and speakers bureau - Wyeth Laboratories and Ortho-McNeil.

Donald E. Craven, MD
Tufts University School of Medicine
Burlington, MA, USA
Speakers bureau - Astellas
Speakers bureau, honoraria, research grant - Pfizer
Consultant- Cubist

CONTINUING EDUCATION
This activity includes text, graphics, and may include multi-media features. There are no fees for participating in or receiving credit for this activity. Click on the arrow in the video screen to your right to review the content presented. You must view all of the content to proceed to the evaluation.
Participants must respond to all evaluation questions to receive a letter of credit. Once the evaluation is completed, SCCM will review your application and email your certificate within 14 days of receipt. For questions, please contact education@sccm.org or call +1-847-827-6869

To complete the evaluation and obtain continuing education, please click here.

Type of activity
This activity was designed as an evidenced-based forum to review expert opinions of MRSA. This activity will focus on increasing knowledge and its application to practice.

Competencies
SCCM supports recommendations that will promote life long learning through continuing education. SCCM promotes activities that encourage the highest quality in education that will enhance knowledge, competence or performance in critical care practice. This activity will meet the following:
-Patient and Family Centered Care
-Practice Applications
-Quality Improvement
-Multiprofessionalism

Target Audience
This continuing medical education offering is intended to meet the needs of physicians, nurses, pharmacists, respiratory therapists, and other providers who care for critically ill patients.

Physicians
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education by Society of Critical Care Medicine (SCCM). SCCM is accredited by ACCME to provide continuing medical education for physicians.
Designation Statement
The Society of Critical Care Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Nurses
SCCM is approved by the California Board of Registered Nursing, Provider No. 8181 and approves this panel for 1.5 contact hours.

Pharmacists
The Society of Critical Care Medicine is accredited by the Accreditation Council of Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Panel Discussion will provide 1.5 contact hours (0.15 CEUs).
UAN: 0236-0000-10-223-H01-P

Click here to begin viewing - Requirements for viewing media